Efficacy Study of TKcell in Advanced Gastric Cancer

Inclusion Criteria: * Written informed consent. * Diagnosis of histologically confirmed adenocarcinoma of the gastric * ECOG performance status of 0 - 2 * At least one definite measurable lesion(s): ≥ 1 cm on spiral CT scan or ≥2cm in physical examination * Adequate liver, renal, bone marrow functions as evidence by the following; Absolute neutrophil count \> 1.5 x 109/L; platelets \> 7.5 x 109/L; Bilirubin less than 2 mg/dL ASAT and/or ALAT \< 5 UNL; serum creatinine ≤ 2 ULN * Minimum life expectancy of 12 weeks * Effective contraception for both male and female subjects if the risk of conception exists Exclusion Criteria: * Brain metastasis and/or leptomeningeal disease (known or suspected) * Previous chemotherapy for gastric cancer except adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment. * Previous oxaliplatin-based chemotherapy * Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to randomization and chemotherapy * HIV antibody (+), Chronic hepatitis * Uncontrolled infection * Concurrent or previous chronic systemic immune therapy, targeted therapy, hormonal therapy not indicated in the study protocol except for contraception * Clinically relevant coronary artery disease, history of myocardial infarction, high risk of uncontrolled arrhythmia * Known hypersensitivity reaction to any of the components of the treatment. * Pregnancy (absence to be confirmed by ß-hCG test) or lactation period * Participation in another clinical study within the 30 days before randomization * Significant disease which, in the investigator's opinion, would exclude the subject from the study